• Artelo Biosciences reported nonclinical osteoarthritis data showing oral ART26.12 reduced pain behaviors over 4 weeks with efficacy comparable to naproxen.
• Preclinical results showed significantly less stomach tissue damage versus naproxen, signaling a potentially improved gastrointestinal safety profile for chronic use.
• Artelo plans a multiple ascending repeat-dose clinical study in healthy volunteers, with enrollment expected to start in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160848PRIMZONEFULLFEED9763234) on July 16, 2026, and is solely responsible for the information contained therein.